Eligo Bioscience
Eligo Bioscience develops a proprietary Gene Editing of the Microbiome (GEM) platform designed to edit the bacterial gene repertoire in vivo. The technology utilizes CRISPR-based precision tools to address diseases triggered or aggravated by specific bacterial genes. The company focuses on therapeutic applications where genetic causality between the microbiome and the host immune system has been established.
Visit websiteParis, France
Biotechnology
Gene Editing
Healthcare
Funding summary
- Total raised
- €50.4M
- Funding rounds
- 3
Investors in Eligo Bioscience
Investors on record for Eligo Bioscience. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Eligo Bioscience?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors